Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) was upgraded by equities researchers at The Goldman Sachs Group to a “hold” rating in a research report issued on Tuesday,Zacks.com reports.
BCAX has been the subject of a number of other research reports. UBS Group restated a “buy” rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Bank of America started coverage on Bicara Therapeutics in a report on Wednesday, March 25th. They set a “buy” rating and a $35.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Wednesday, April 8th. Guggenheim started coverage on Bicara Therapeutics in a report on Monday. They set a “buy” rating and a $42.00 price objective for the company. Finally, Wedbush reiterated an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a report on Tuesday, March 31st. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $30.27.
Read Our Latest Research Report on BCAX
Bicara Therapeutics Stock Down 6.3%
Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) last posted its earnings results on Monday, May 11th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Equities analysts expect that Bicara Therapeutics will post -3.17 earnings per share for the current year.
Insiders Place Their Bets
In related news, insider David Raben sold 5,500 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $22.88, for a total value of $125,840.00. Following the completion of the transaction, the insider owned 55,286 shares in the company, valued at $1,264,943.68. This trade represents a 9.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Claire Mazumdar sold 15,000 shares of the firm’s stock in a transaction on Monday, April 20th. The stock was sold at an average price of $23.61, for a total value of $354,150.00. Following the completion of the transaction, the chief executive officer owned 362,152 shares of the company’s stock, valued at $8,550,408.72. This trade represents a 3.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 174,310 shares of company stock worth $3,459,283. 15.50% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Bicara Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BCAX. AQR Capital Management LLC purchased a new position in Bicara Therapeutics in the 1st quarter worth $248,000. Woodline Partners LP raised its stake in Bicara Therapeutics by 26.5% in the 1st quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock worth $4,543,000 after acquiring an additional 72,998 shares during the last quarter. Geode Capital Management LLC raised its stake in Bicara Therapeutics by 36.8% in the 2nd quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock worth $6,248,000 after acquiring an additional 180,833 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Bicara Therapeutics by 26.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 27,458 shares of the company’s stock worth $255,000 after acquiring an additional 5,664 shares during the last quarter. Finally, Legal & General Group Plc raised its stake in Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares during the last quarter.
Bicara Therapeutics Company Profile
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Read More
- Five stocks we like better than Bicara Therapeutics
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
